Table 1. Baseline characteristics of 117 patients with PA-induced HSOS at the time of diagnosis.
| Variables | All patients | Survival outcome | ||
|---|---|---|---|---|
| Survival group | Death group | P value* | ||
| Number of patients | 117 | 81 | 36 | |
| Age, years | 61.00 (50.50–64.50) | 60.00 (49.50–64.50) | 61.00 (51.25–64.75) | 0.89 |
| Male sex, n (%) | 75.00 (64.00%) | 50.00 (61.70%) | 25.00 (69.40%) | 0.42 |
| Erythrocytes, 1012/L | 4.46 (4.12–4.91) | 4.52 (4.11–4.83) | 4.45 (4.14–5.05) | 0.69 |
| Hemoglobin, g/L | 139.00 (122.50–150.00) | 137.50 (122.25–149.00) | 141.00 (121.50–159.00) | 0.32 |
| Leukocyte, 109/L | 6.08 (4.66–8.21) | 5.74 (4.44–7.19) | 7.51 (5.30–8.73) | 0.20 |
| Platelet, 109/L | 104.00 (75.00–142.00) | 106.00 (75.50–155.50) | 98.00 (72.00–128.00) | 0.31 |
| PT, S | 16.60 (15.08–18.38) | 15.90 (14.90–18.10) | 17.00 (16.20–18.70) | 0.03 |
| INR | 1.35 (1.19–1.53) | 1.29 (1.17–1.46) | 1.42 (1.31–1.60) | 0.02 |
| ALT, U/L | 66.50 (37.00–146.25) | 66.00 (33.00–145.00) | 78.00 (42.00–194.00) | 0.23 |
| AST, U/L | 91.00 (53.00–165.00) | 79.00 (48.00–162.00) | 111.00 (67.25–188.00) | 0.23 |
| Total bilirubin, μmol/L | 36.35 (22.85–67.35) | 34.31 (21.71–56.32) | 43.95 (26.75–116.90) | 0.03 |
| ALB, g/L | 31.55 (28.30–35.20) | 32.85 (28.80–35.58) | 29.85 (27.25–32.53) | 0.18 |
| Urea, mmol/L | 5.95 (4.36–8.18) | 5.97 (4.48–7.62) | 5.86 (4.22–8.96) | 0.28 |
| Creatinine, μmol/L | 77.50 (61.07–93.08) | 75.50 (62.20–91.70) | 81.95 (62.08–99.40) | 0.14 |
| Child-Pugh, n (%) | 0.08 | |||
| A | 19.00 (17.12) | 17.00 (22.37) | 2.00 (5.71) | |
| B | 75.00 (67.57) | 49.00 (64.47) | 26.00 (74.29) | |
| C | 17.00 (15.31) | 10.00 (13.16) | 7.00 (20.00) | |
| Severity grading†, n (%) | <0.01 | |||
| Mild | 35.00 (30.17) | 29.00 (36.25) | 6.00 (16.67) | |
| Moderate | 37.00 (31.90) | 29.00 (36.25) | 8.00 (22.22) | |
| Severe | 21.00 (18.10) | 11.00 (13.75) | 10.00 (27.78) | |
| Very severe | 23.00 (19.83) | 11.00 (13.75) | 12.00 (33.33) | |
| MELD | 11.32 (8.13–15.63) | 10.12 (6.60–14.84) | 15.28 (9.69–17.29) | <0.01 |
Continuous variables are presented as median (25th–75th percentiles), and categorical variables are presented as count (percentage). *, the P values refer to t-test or chi-square test between patients in the survival group and death group; †, refers to the new criteria for severity grading of HSCT-related HSOS in adults (19). Normal ranges: erythrocytes: (3.0–5.5)×1012/L; hemoglobin: 110–160 g/L; leukocyte: (4.0–10.0)×109/L; platelet: (100.0–300.0)×109/L; prothrombin time (PT): 11–16 S; international normalized ratio (INR): 0.80–1.31; alanine aminotransferase (ALT): 5–35 U/L; aspartate aminotransferase (AST): 8–40 U/L; total bilirubin (T-BIL): 5.1–19 μmol/L; albumin (ALB): 35–55 g/L; urea: 2.9–8.2 mmol/L; creatinine: 44–106 µmol/L. PA, pyrrolizidine alkaloid; HSOS, hepatic sinusoidal obstruction syndrome; MELD, model for end-stage liver disease.